Long-term outcome of first-line sildenafil monotreatment for pulmonary arterial hypertension

Long-term outcome of first-line sildenafil monotreatment for pulmonary arterial hypertension - Sildenafil as a first-line therapy for PAH

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005803

Enrollment

Registered

2011-06-19

Start date

2003-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: pulmonary arterial hypertension

Exclusion criteria

Exclusion criteria: Eisenmenger syndrome

Design outcomes

Primary

Measure	Time frame
hemodynamic parameters obtained by right-side heart catheterization, six minutes walk distance, serum BNP level, the occurrence of events such as the addition of epoprostenol, hospitalization for right-side heart failure, and survival	—

Countries

Japan

Outcome results